eicosapentaenoic acid ethyl ester has been researched along with Heart Failure in 4 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed the effects of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) on normal cardiac function (part 1) and congestive heart failure (CHF) (part 2) through electrocardiogram analysis and determination of EPA, DHA, and arachidonic acid (AA) concentrations in rat hearts." | 7.80 | Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats. ( Hirakawa, E; Janjua, N; Kabuto, H; Mankura, M; Takayama, F; Yamanushi, TT, 2014) |
| "The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA])." | 5.05 | Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. ( Agarwala, A; Al Rifai, M; Gulati, M; Jia, X; Liu, J; Virani, SS, 2020) |
| "This study assessed the effects of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) on normal cardiac function (part 1) and congestive heart failure (CHF) (part 2) through electrocardiogram analysis and determination of EPA, DHA, and arachidonic acid (AA) concentrations in rat hearts." | 3.80 | Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats. ( Hirakawa, E; Janjua, N; Kabuto, H; Mankura, M; Takayama, F; Yamanushi, TT, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, X | 1 |
| Al Rifai, M | 1 |
| Liu, J | 1 |
| Agarwala, A | 1 |
| Gulati, M | 1 |
| Virani, SS | 1 |
| Matsuo, N | 1 |
| Miyoshi, T | 1 |
| Takaishi, A | 1 |
| Kishinoue, T | 1 |
| Yasuhara, K | 1 |
| Tanimoto, M | 1 |
| Nakano, Y | 1 |
| Onishi, N | 1 |
| Ueeda, M | 1 |
| Ito, H | 1 |
| Haslam, A | 1 |
| Prasad, V | 1 |
| Yamanushi, TT | 1 |
| Kabuto, H | 1 |
| Hirakawa, E | 1 |
| Janjua, N | 1 |
| Takayama, F | 1 |
| Mankura, M | 1 |
1 review available for eicosapentaenoic acid ethyl ester and Heart Failure
| Article | Year |
|---|---|
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Child; Cholesterol, LDL; Denerva | 2020 |
3 other studies available for eicosapentaenoic acid ethyl ester and Heart Failure
| Article | Year |
|---|---|
High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction.
Topics: 8,11,14-Eicosatrienoic Acid; Aged; Aged, 80 and over; Arachidonic Acid; Cause of Death; Docosahexaen | 2021 |
Confirmatory Trials for Drugs Approved on a Single Trial.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases | 2019 |
Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dietary Supplements; Disease Models, Animal; Docos | 2014 |